Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

Next Previous
Search
Trial Profile

A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Cisplatin; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Jun 2024 Results (At the January 31, 2024) assessing efficacy and safety of consolidation nivolumab versus observation following neoadjuvant chemotherapy plus nivolumab in patients with unresectable stage III NSCLC presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 20 Apr 2024 Planned End Date changed from 3 Jan 2024 to 31 Jan 2025.
    • 20 Apr 2024 Planned primary completion date changed from 3 Jan 2024 to 31 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top